The blood test is designed to detect a phosphorylated tau 217 (pTau 217), a common marker of Alzheimer’s disease, through a low-invasive and accessible process. According to Heather Nelson ...

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C., April 2, 2025 /PRNewswire ...

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by ...

The ability to detect brain-derived pTau species directly from blood represents a transformative step in early detection Phosphorylated tau has emerged as a critical biomarker for early detection ...

"We designed our Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test to help physicians and patients with signs and symptoms of cognitive decline obtain an AD diagnosis much earlier when ...

Fujirebio announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse G pTau 217/ß-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for ...

The pTau 217 Blood Test is something that’s been worked on for years at ARUP Laboratories on the University of Utah’s campus. “We need to make sure that the performance characteristics of ...

SALT LAKE CITY, April 21, 2025 /PRNewswire/ -- ARUP Laboratories now provides a blood test for phosphorylated tau 217 (pTau 217) to assist in identifying whether cognitive decline symptoms in ...

Spear Bio Inc., announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). This recognizes the test's potential to address ...